MinervaX announces that the company has raised DKK 16 million (EUR 2.2 million) for the development of its Group B Streptococcal Vaccine. The financing was a combination of an equity financing led by Novo Seeds, the seed arm of Novo A/S, supported by Sunstone Capital and LF Investment.
- MinervaX Provides Clinical Update on its Maternal GBS Vaccine 14/02/2022
- MVX0004 Phase II 11/02/2022
- MinervaX provides clinical and leadership update 07/10/2021
- MVX0003 Phase I 01/02/2021
- MinervaX announces completion of 47.4 mEUR financing 15/12/2020